ATHIRA PHARMA INC. - COMMON STOCK

0,2760

23-мая-25 13:45:00

15 мин. задержка

Акции

+0,0055

+2,03%

Сегодняшний диапазон

0,2635 - 0,2890

ISIN

N/A

Источник

NASDAQ

Athira Pharma to Present Data from First-in-Human Phase 1 Clinical Trial of ATH-1105 at the 4th Annual ALS Drug Development Summit

13 май 2025 08:00:00 Источник Nasdaq GlobeNewswire
Athira Pharma Reports First Quarter 2025 Financial Results and Pipeline and Business Updates

09 май 2025 13:05:00 Источник Nasdaq GlobeNewswire
Athira Pharma Reports Full Year 2024 Financial Results and Pipeline and Business Updates

27 фев 2025 13:05:00 Источник Nasdaq GlobeNewswire
Athira Pharma Presents Preclinical Data Highlighting Neuroprotective Effects of ATH-1105 in Models of ALS at Motor Neurone Disease Association’s 35th International Symposium on ALS/MND

06 дек 2024 14:30:00 Источник Nasdaq GlobeNewswire
Athira Pharma Reports Third Quarter 2024 Financial Results and Pipeline and Business Updates

07 ноя 2024 13:05:02 Источник Nasdaq GlobeNewswire
Athira Pharma to Present Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting

22 окт 2024 04:00:00 Источник Nasdaq GlobeNewswire
Athira Pharma to Focus on Advancement of ATH-1105 for the Treatment of Neurodegenerative Diseases

17 сен 2024 06:00:00 Источник Nasdaq GlobeNewswire
Athira Pharma Announces Topline Results from Phase 2/3 LIFT-AD Clinical Trial of Fosgonimeton for Mild-to-Moderate Alzheimer’s Disease

03 сен 2024 13:01:00 Источник Nasdaq GlobeNewswire
Athira Pharma Reports Second Quarter 2024 Financial Results and Pipeline and Business Updates

01 авг 2024 13:05:00 Источник Nasdaq GlobeNewswire
Athira Pharma Presents Preclinical Data Demonstrating New Insights into the Mechanism by Which Fosgonimeton Protects Neurons from Alzheimer’s Disease-Related Pathology at the Alzheimer’s Association International Conference (AAIC) 2024

31 июл 2024 05:05:00 Источник Nasdaq GlobeNewswire
Athira Pharma Announces Last Patient Completed LIFT-AD Clinical Trial of Fosgonimeton in Mild-to-Moderate Alzheimer’s Disease

09 июл 2024 04:00:00 Источник Nasdaq GlobeNewswire
Athira to Host Webinar Highlighting Potential for Fosgonimeton to Protect and Preserve Neuronal Health in Mild-to-Moderate Alzheimer’s Disease Patients

12 июн 2024 04:00:00 Источник Nasdaq GlobeNewswire
Athira Pharma Completes First Cohort in Phase 1 Clinical Trial of ATH-1105, an Oral, Small Molecule Drug Candidate for Amyotrophic Lateral Sclerosis (ALS)

11 июн 2024 04:00:00 Источник Nasdaq GlobeNewswire
Athira Pharma to Participate in Upcoming June Conferences

29 май 2024 04:00:00 Источник Nasdaq GlobeNewswire
Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action

17 май 2024 14:00:00 Источник Nasdaq GlobeNewswire
Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates

15 май 2024 13:05:00 Источник Nasdaq GlobeNewswire
Athira Pharma to Participate in Upcoming May Conferences

02 май 2024 04:00:00 Источник Nasdaq GlobeNewswire
Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer

15 апр 2024 04:00:00 Источник Nasdaq GlobeNewswire
Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease

11 апр 2024 04:00:00 Источник Nasdaq GlobeNewswire
Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting

03 апр 2024 04:00:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.